Asset
Pariglasgene Brecaparvovec
Ultragenyx Pharmaceutical Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05139316 | phase3 | completed | 2021-11-08 | 2024-02-20 | Ultragenyx Pharmaceutical Inc | A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) |
| NCT03517085 | phase1_2 | completed | 2018-05-18 | 2021-11-02 | Ultragenyx Pharmaceutical Inc | Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa) |
FDA applications (0)
This company has no applications containing this asset.